Overview

Divided Dose of TRAVATAN®

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the incremental dosing of travoprost ophthalmic solution versus once a day dosing of TRAVATAN® in lowering intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Phase:
Phase 2
Details
Lead Sponsor:
Alcon Research
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions
Travoprost